Every year in September, the HIV Cure Research Center organizes a lively symposium in the picturesque city of Ghent, Belgium. Since the pandemic outbreak of SARS-CoV-2, the lab has invested heavily in the initiation of key research in COVID-19 and a symposium can not be organized as before. Therefore, we decided to switch to a hybrid HIV-SARS-CoV-2 online symposium, which will take place the 22nd of October, in which we discuss key aspects of COVID-19 pathogenesis and HIV cure.
We will walk you through the basic principles of COVID-19 pathophysiology, animal models for COVID-19 and COVID-19 protection by nanobodies and a vaccine. In addition, we will of course focus on HIV reservoirs and cure.
Latent HIV reservoir is able to refuel infection once the treatment is stopped and therefore a better understanding of both, the composition and the size of this reservoir will be important to aid the development of cure strategies as well as to monitor the efficacy of therapeutic interventions to reduce the HIV reservoir. Therefore, we will address key aspects of viral rebound and how to monitor it. Finally, we will discuss the status of HIV cure clinical trials with emphasis on novel immunotherapeutic approaches.
The HIV and SARS-CoV-2 hybrid symposium will comprehensively summarizes the state of the art in COVID-19 and HIV cure strategies.
Program
| SARS-CoV-2 HOT TOPICS - Chaired by Sarah Gerlo and Wojciech Witkowski | |
|---|---|
|
09.00 - 09.05 |
Welcome and Introduction Linos Vandekerckhove, Ghent University Hospital, Ghent, Belgium |
|
09.05 - 09.30 |
From HIV to SARS-CoV-2, from one pandemia to another Nathan Clumeck, Saint-Pierre University Hospital-ULB, Belgium Q&A |
|
09.30 - 09.55 |
COVID-19 diseases and opportunities for immunotherapy Bart Lambrecht, Ghent University, Belgium Q&A |
|
09.55 - 10.20 |
COVID-19 vaccine development efforts at J&J Hanneke Schuitemaker, Global Head Viral Vaccines Discovery & Translational Medicine, Janssen Vaccines & Prevention, Professor in Virology at Amsterdam University Medical Center Q&A |
|
10.20 - 10.45 |
Break |
| SARS-CoV-2 THERAPEUTIC APPROACHES AND SOCIETAL IMPACT - Chaired by Steven Callens and Kevin Ariën | |
|---|---|
|
10.45 - 11.10 |
Animal models for SARS-CoV-2 compound and vaccine development screening Johan Neyts, KU Leuven, Leuven, Belgium Q&A |
|
11.10 - 11.35 |
Nanobodies to treat SARS-CoV-2 moving towards clinical trials Xavier Saelens, VIB and Ghent University, Ghent, Belgium Q&A |
|
11.35 - 12.00 |
Balance between COVID-19 diseases and societal impact Lieven Annemans, Ghent University and Brussels University (VUB), Belgium Q&A |
|
12.00 - 13.00 |
Break/Satellite Symposium Remdesivir for the treatment of COVID-19: Tomas Cihlar (Vice President Discovery Virology, Gilead Sciences) Gilead’s HIV Cure Strategy: Wade Blair (Executive Director Discovery Virology, Gilead Sciences) |
| UNMASKING THE HIV VIRAL RESERVOIR - Chaired by Linos Vandekerckhove and Marion Pardons | |
|---|---|
|
13.00 - 13.25 |
Distinct viral reservoirs in individuals with spontaneous control of HIV-1 Mathias Lichterfeld, Harvard Medical School, Boston, US Q&A |
|
13.25 - 13.50 |
How to link clonal proliferation, intact viral sequences and HIV-1 viral rebound Basiel Cole, Ghent University, Ghent, Belgium Q&A |
|
13.50 - 14.15 |
Implementing HIV-1 intact proviral assays in clinical trials and clinical practice Robert Siliciano, Johns Hopkins University, Maryland, US Q&A |
|
14.15 - 14.30 |
Break |
| IMMUNE STRATEGIES FOR SARS-CoV-2 AND HIV - Chaired by Guido Vanham and Gilles Darcis | |
|---|---|
|
14.30 - 14.55 |
TCR adapted therapies to cure HIV-1 Lucy Dorrell, University of Oxford, Oxford, UK Q&A |
|
14.55 - 15.20 |
Immunocorrelates of SARS-CoV-2 protection Susan P. Ribeiro, Emory University, Atlanta, US Q&A |
|
15.20 - 15.45 |
Current status on HIV-1 Cure clinical trials Linos Vandekerckhove, Ghent University and Ghent University Hospital, Ghent, Belgium Q&A |
|
15.45 - 16.00 |
Break |
|
16.00 - 16.15 |
Closing and voting results Linos Vandekerckhove, Ghent University and Ghent University Hospital, Ghent, Belgium |
Sponsored by:
WERELDWIJD LEVEN 37 MILJOEN MENSEN MET HIV. STEUN HET FONDS HIV ONTRAFELEN en Help hen.
Door de COVID-19 maatregelen zal de 7de editie pas in december 2021 plaatsvinden.
Doneren
-
Of via overschrijving:
Universiteitsfonds UGent - IBAN BE26 3900 9658 0329
- BIC BBRUBEBB
- Met duidelijke vermelding: HIVOntrafelen
- Giften vanaf 40 euro jaarsbasis zijn 60% fiscaal aftrekbaar in 2020 . Meer informatie: www.ugent.be/iksteunmee
Dutch 
English